Informatie:
Fout:
ID
33954
Beschrijving
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01646450
Link
https://clinicaltrials.gov/show/NCT01646450
Trefwoorden
Versies (1)
- 09-01-19 09-01-19 -
Houder van rechten
See clinicaltrials.gov
Geüploaded op
9 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Non-Small Cell Lung Cancer NCT01646450
Eligibility Non-Small Cell Lung Cancer NCT01646450
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small Cell Lung Cancer NCT01646450
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Non-small cell lung cancer recurrent TNM clinical staging | Non-Small Cell Lung Carcinoma Progressive TNM clinical staging
Item
recurrent or progressive non-small cell lung cancer stage iv or iiib patients.
boolean
C0278517 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0007131 (UMLS CUI [2,1])
C0205329 (UMLS CUI [2,2])
C3258246 (UMLS CUI [2,3])
C3258246 (UMLS CUI [1,2])
C0007131 (UMLS CUI [2,1])
C0205329 (UMLS CUI [2,2])
C3258246 (UMLS CUI [2,3])
EGFR gene mutation Positive
Item
positive egfr mutation.
boolean
C3266992 (UMLS CUI [1,1])
C1514241 (UMLS CUI [1,2])
C1514241 (UMLS CUI [1,2])
Absence Cancer treatment Systemic
Item
no previous systemic anticancer therapy.
boolean
C0332197 (UMLS CUI [1,1])
C0920425 (UMLS CUI [1,2])
C0205373 (UMLS CUI [1,3])
C0920425 (UMLS CUI [1,2])
C0205373 (UMLS CUI [1,3])
Age
Item
male and female patients aged over 70 years.
boolean
C0001779 (UMLS CUI [1])
Measurable lesion | Measurable lesion Quantity Therapeutic radiology procedure Absent | Exception Disease Progression
Item
measurable lesion according to recist with at least one measurable lesion not previously irradiated, unless disease progression has been documented at that site.
boolean
C1513041 (UMLS CUI [1])
C1513041 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C1522449 (UMLS CUI [2,3])
C0332197 (UMLS CUI [2,4])
C1705847 (UMLS CUI [3,1])
C0242656 (UMLS CUI [3,2])
C1513041 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C1522449 (UMLS CUI [2,3])
C0332197 (UMLS CUI [2,4])
C1705847 (UMLS CUI [3,1])
C0242656 (UMLS CUI [3,2])
Informed Consent
Item
provision of written informed consent.
boolean
C0021430 (UMLS CUI [1])
Lung Diseases, Interstitial
Item
evidence of clinically active interstitial lung diseases (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded).
boolean
C0206062 (UMLS CUI [1])
Severe allergy Icotinib | Severe allergy Excipient Icotinib
Item
known severe hypersensitivity to icotinib or any of the excipients of this product.
boolean
C2945656 (UMLS CUI [1,1])
C2604307 (UMLS CUI [1,2])
C2945656 (UMLS CUI [2,1])
C0015237 (UMLS CUI [2,2])
C2604307 (UMLS CUI [2,3])
C2604307 (UMLS CUI [1,2])
C2945656 (UMLS CUI [2,1])
C0015237 (UMLS CUI [2,2])
C2604307 (UMLS CUI [2,3])
Disease Study Subject Participation Status Unfavorable | Laboratory test finding Study Subject Participation Status Unfavorable
Item
evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.
boolean
C0012634 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C3640815 (UMLS CUI [1,3])
C0587081 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C3640815 (UMLS CUI [2,3])
C2348568 (UMLS CUI [1,2])
C3640815 (UMLS CUI [1,3])
C0587081 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C3640815 (UMLS CUI [2,3])